Similar biochemical changes associated with multidrug resistance in human breast cancer cells and carcinogen-induced resistance to xenobiotics in rats.

Cowan, Kenneth H.; Batist, Gerald; Tulpule, Anil; Sinha, Birandra K.; Myers, Charles E.

doi:10.1073/pnas.83.24.9328

Cited by 223 publications

(139 citation statements)

References 37 publications

Supporting

Mentioning

130

Contrasting

Unclassified

Order By: Relevance

“…Rhabdomyosarcoma (RMS) RH-30 cell line was a gift from St. Jude Children's Research Hospital (Memphis, TN). Both DOX-selected multidrug resistant (MDR) cell subline K562/A02 13 and MCF-7/ADR 14,15 were purchased from the Institute of Hematology, Chinese Academy of Medical Sciences (Tianjin, China). The VCR-selected MDR KB/VCR 16 subline was obtained from Zhongshan University of Medical Sciences (Guangzhou, China).…”

Section: Cell Lines and Culturementioning

confidence: 99%

SH‐7, a new synthesized shikonin derivative, exerting its potent antitumor activities as a topoisomerase inhibitor

Yang

Chen

Duan

et al. 2006

Intl Journal of Cancer

View full text Add to dashboard Cite

1-(1,4-dihydro-5,8-dihydroxy-1,4-dioxonaphthalen-2-yl)-4-methylpent-3-enylfuran-2-caroxylate (SH-7), a new naphthoquinone compound, derived from shikonin, exhibited obvious inhibitory actions on topoisomerase II (Topo II) and topoisomerase I (Topo I), which were stronger than its mother compound shikonin. Notably, the SH-7's inhibitory potency on Topo II was much stronger than that on Topo I. In addition, SH-7 significantly stabilized Topo II-DNA cleavable complex and elevated the expression of phosphorylated-H2AX. The in vitro cell-based investigation demonstrated that SH-7 displayed wide cytotoxicity in diversified cancer cell lines with the mean IC 50 value of 7.75 lM. One important finding is SH-7 displayed significant cytotoxicity in the 3 MDR cell lines, with an average IC 50 value nearly equivalent to that of the corresponding parental cell lines. The average resistance factor (RF) of SH-7 was 1.74, which was much lower than those of reference drugs VP-16 (RF 145.92), ADR (RF 105.97) and VCR (RF 197.39). Further studies illustrated that SH-7 had the marked apoptosis-inducing function on leukemia HL-60 cells, which was validated to be of mitochondria-dependence. The in vivo experiments showed that SH-7 had inhibitory effects on S-180 sarcoma implanted to mice, SMMC-7721, BEL-7402 human hepatocellular carcinoma and PC-3 human prostate cancer implanted to nude mice. Taken together, these results suggest that SH-7 induces DSBs as a Topo II inhibitor, which was crucial to activate the apoptotic process, and subsequently accounts for its both in vitro and in vivo antitumor activities. The well-defined Topo II inhibitory activity, antitumor effects particularly with its obvious anti-MDR action, better solubility and less toxicity make SH-7 as a potential antitumor drug candidate for further research and development.

show abstract

Section: Cell Lines and Culturementioning

confidence: 99%

SH‐7, a new synthesized shikonin derivative, exerting its potent antitumor activities as a topoisomerase inhibitor

Yang

Chen

Duan

et al. 2006

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…As CDDP exerts its cytoxicity by producing intrastrand crosslinks in DNA strands (Sundquist & Lippard, 1990), whilst adriamycin intercalates between neighbouring DNA bases (Muller, 1975), the mechanisms of induced drug resistance are different. In the case of CDDP increased resistance of tumour cells was shown to result often from a higher cellular efficiency in excising Pt-DNA adducts (Masuda et al, 1988, Eastman & Schulte, 1988Sekiya et al, 1989), whereas in cells resistant to adriamycin an enhanced capacity for drug transport out of the cells was supposed to be the main mechanism responsible for drug resistance (Inaka et al, 1979;Cowan et al, 1986). it is conceivable that this property of adriamycin-resistant cells is associated with alterations in membrane metabolism and, thus, could explain the decreased concentrations of the PMEs and PDEs, which are both metabolites of membrane-bound phospholipids (for an overview see Van den Bosch, 1974;Cohen, 1988).…”

Section: Uninfluenced Tumour Growthmentioning

confidence: 99%

31P nuclear magnetic resonance spectroscopy, histology and cytokinetics of a xenografted hypopharynx carcinoma following treatment with cisplatin: comparison in three sublines with increasing resistance

Tausch-Treml

Köpf-Maier²,

Baumgart³

et al. 1991

Br J Cancer

View full text Add to dashboard Cite

Glickson, 1989). Some previous studies revealed that administration of chemotherapy was often accompanied by reenergisation of the tumours, whilst in the case of certain regimens of chemotherapy and, especially, of hyperthermia, contrary effects were observed (for an overview see Steen, 1989). The PMEs as precursors of cell membrane phospholipid synthesis generally showed a decline following chemotherapy (Lutz et al., 1988;Daly et al., 1990). However, to our knowledge, only Evelhoch and coworkers (1987) investigated whether these changes are response-specific markers indicating significant tumour regression following chemotherapy or whether they are related to an unspecific action of chemotherapy, occurring independently of drug cytotoxicity. They studied the in vivo response of a mammary adenocarcinoma sensitive to adriamycin in comparison to a drug-resistant subline following treatment with adriamycin by 31P NMR spectroscopy. As they could not find any changes in the phosphorus metabolism in the resistant subline following chemotherapy, the 31P NMR spectroscopic effects observed in the sensitive subline were assigned as response-specific markers for chemotherapy. Moreover, Cohen et al. (1986) reported differences in the levels of phospholipids and PCr in a MCF-7 mammary carcinoma cell line resistant to adriamycin in comparison to the sensitive wild type. This result was confirmed in Evelhoch's study (1987) , 1984;Toohill et al., 1987).In the present study we investigated the phosphorus metabolism, by 31P NMR spectroscopy, in a xenografted human epidermoid carcinoma of the hypopharynx, growing subcutaneously in athymic mice, and in two sublines of the tumour with an increasing resistance to CDDP. In contrast to the above mentioned studies, the sublines exhibited only partial resistance to CDDP, which is closer to the situation observed in human patient tumours. By comparing three tumour lines with continuously decreasing sensitivity to CDDP, we expected to be able to assign the phenomena related to drug resistance regarding the initial levels of the phosphorus containing metabolites in the tumours and the alterations induced by CDDP with regard to the therapeutic efficacy. Parallel to NMR spectroscopy, tumour cytokinetics and histology were investigated in order to relate the changes observed in the 31P NMR spectra with generally accepted indicators of tumour response. Materials and methodsTumour system and chemotherapy The investigations were performed on a moderately differentiated carcinoma of the hypopharynx which had been established from an untreated patient. The tumour was transplanted serially in male athymic mice (NMRI, nu/nu) and passaged by implanting tumour suspensions into the flank of the animals. From this tumour which was highly sensitive to cisplatin (CDDP), two sublines with an increasing degree of resistance to the drug were selected experimentally in vivo by repeated course treatment with CDDP over several generations. The subline with the lower resistance was maintained

show abstract

“…(Hayes & Wolf 1988). In certain cases concomitant over expression of both GST pi and mdr-1 mRNA have been observed (Cowan et al, 1986). Over expression of both mdr-l and GST has also been seen in carcinogen-induced preneoplastic lesions in rat liver indicating that there may be co-ordinate expression of these proteins (Kitahara et al, 1984).…”

mentioning

confidence: 99%

Glutathione-s-transferase pi expression in leukaemia: a comparative analysis with mdr-1 data

Holmes

Wareing²,

Jacobs³

et al. 1990

Br J Cancer

View full text Add to dashboard Cite

Summary Drug resistance in haemopoietic cells may be partly related to the expression of the glutathione-stransferase (GST) pi and mdr-l genes. We have used RNA slot blotting techniques to investigate the expression of GST pi in peripheral blood and bone marrow of eleven normal subjects, nine patients with myelodysplastic syndrome (MDS), eighteen patients with acute myeloblastic leukaemia (AML), and thirty-two patients with chronic lymphocyte leukaemia (CLL). We found increased expression of GST pi in 8 of 9 MDS, (7 peripheral blood, I bone marrow) 12

show abstract

Similar biochemical changes associated with multidrug resistance in human breast cancer cells and carcinogen-induced resistance to xenobiotics in rats.

Cited by 223 publications

References 37 publications

SH‐7, a new synthesized shikonin derivative, exerting its potent antitumor activities as a topoisomerase inhibitor

SH‐7, a new synthesized shikonin derivative, exerting its potent antitumor activities as a topoisomerase inhibitor

31P nuclear magnetic resonance spectroscopy, histology and cytokinetics of a xenografted hypopharynx carcinoma following treatment with cisplatin: comparison in three sublines with increasing resistance

Glutathione-s-transferase pi expression in leukaemia: a comparative analysis with mdr-1 data

Contact Info

Product

Resources

About